NCT07069270

A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy

A Prospective, Single-center, Single-arm Clinical Study of Adebrelimab in Combination With Vunakizumab and Chemotherapy as First-line Treatment for Extensious-stage Small Cell Lung Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, single-center, single-arm clinical trial, with a planned enrollment of 28 cases.The first Adebrelimab +Vunakizumab +EC was administered within 72 hours after enrollment for 4 to 6 cycles.At the end of the combination phase, non-PD subjects entered the maintenance treatment period of Adebrelimab plus Vunakizumab.Treatment will continue until any of the following situations occur: disease progression in the subject, intolerable toxic and side effects, comorbidiments that affect further treatment, the investigator's decision to withdraw the subject from the study, or other reasons for non-compliance with the study treatment or the study procedures or protocols.

Conditions

• Vunakizumab
• Adebrelimab
• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Vunakizumab (IL-17A inhibitor)	Vunakizumab , 240mg, D1, subcutaneous injection, Q4W.
DRUG	Adebrelimab	Adebrelimab, 1200 mg, D1, intravenous drip, Q3W
DRUG	Chemotherapy	Etoposide, 100mg /m², D1-3, IV, Q3W. Carboplatin, AUC 5, D1, IV, Q3W

Timeline

• Start date: 2025-09-01
• Primary completion: 2026-06-01
• Completion: 2028-01-01
• First posted: 2025-07-16
• Last updated: 2025-07-16